Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Patient Reported Outcome Measures × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 2 Other hematologic neoplasm 2 Myeloid 2 Lymphoid 2 Head & Neck 1 Gastrointestinal 1 Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 288 Paclitaxel 249 Cyclophosphamide 237 Docetaxel 231 Capecitabine 192 Carboplatin 173 Letrozole 155 Fulvestrant 148 Doxorubicin 137 Bevacizumab 116 Anastrozole 99 Tamoxifen 97 Vinorelbine 93 Epirubicin 91 pertuzumab 89 pembrolizumab 89 Gemcitabine 88 exemestane 87 Albumin-Bound Paclitaxel 76 Lapatinib 73 Radiotherapy 69 130-nm albumin-bound paclitaxel 68 eribulin 65 palbociclib 59 Cisplatin 55 pyrotinib 52 Taxes 50 Everolimus 46 Drug Therapy 43 Goserelin 42

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05932667 2023-12-21

DEMETER

Institut Curie

Phase 2 Terminated

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡